A Phase 1 interventional study of 1200mg of TQB2928 injection+Anlotinib and 1800mg of TQB2928 injection+Anlotinib in Osteosarcoma and Other Solid Tumors, sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.. Terminated at 5 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-12-12.
Sponsored by Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 60 studies in Osteosarcoma with a site in China — 22 open to participants now, 26 under way, none of them phase 3. Osteosarcoma · China.
Among the 60 studies in Osteosarcoma with a site in China, this one is the 31st largest by enrollment of the 42 interventional ones that give a count, is one of 12 that started in 2024, is one of 10 in phase 1, and was the 45th registered.
488 studies on the registry are indexed under Osteosarcoma; 123 are open to participants now.
Browse Osteosarcoma studies →22 of the 60 studies in Osteosarcoma with a site in China are open now. Recruiting first, the newest first:
Peking University First Hospital · Sites in China
Ages 10–80
Peking University People's Hospital · Sites in China
Ages 12–65
Essen Biotech · Sites in China
Ages 21–90
Sun Yat-sen University · Sites in China
Ages 14–70
Peking University People's Hospital · Sites in China
Ages 14–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 100 Osteosarcoma studies recruiting now, 41 (41%) set no upper age limit and 55 (55%) stop at 75 or younger; 75 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
60 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 26 · Phase 3 2 · Phase 4 1
First in 2000; this study’s year is marked. 12 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 20 is below the median of 40 across 354 interventional studies indexed under Osteosarcoma.
Median enrollment 44 across the 42 interventional studies, 100 across the 18 observational. Of the 17 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 60 have an industry lead sponsor. The 10 most frequent:
This study is registered under Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., one of the names counted as Sino Biopharmaceutical Limited. Under that name alone:
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. is the lead sponsor of 53 studies on the registry; 29 are open to participants now.
Sino Biopharmaceutical Limited has 1 study filed under Osteosarcoma — fewer than ten, so there is no comparison to draw.
4 of the studies in Osteosarcoma with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07602049Sun Yat-sen UniversityCryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma | 2026-11-30 |
| NCT05590572Second Affiliated Hospital, School of Medicine, Zhejiang UniversityA Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma | 2026-12 |
| NCT07648069Sun Yat-sen UniversityTumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma | 2026-12-31 |
| NCT07479732Peking University People's HospitalApatinib Combined With Liposomal Irinotecan for Refractory or Metastatic Osteosarcoma | 2027-03-05 |
Add all 4 to your calendar (.ics) → With an account.
Among the 60 studies in Osteosarcoma with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other relapsed/metastatic solid tumors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The requirements for front-line treatment received by subjects are as follows:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
21 days as a treatment cycle.
Drug: 1200mg of TQB2928 injection+Anlotinib
21 days as a treatment cycle.
Drug: 1800mg of TQB2928 injection+Anlotinib
TQB2928 is a novel humanized immunoglobulin G4 (IgG4) subtype monoclonal antibody targeting Cluster of Differentiation 47 (CD47).
TQB2928 is a novel humanized igG4 subtype monoclonal antibody targeting CD47.
Cohort 1: Progression-Free Survival (PFS) of 6 months
Cohort 1: Kaplan-Meier method was used to plot the survival curve, in which the cumulative survival rate and 95% confidence interval corresponding to the progression-free survival time of 6 months were obtained.
Time frame: Up to 6 months
Cohort 2: Overall response rate (ORR)
Cohort 2: The percentage of subjects with complete (CR) or partial response (PR) as determined by the investigator according to the RECIST 1.1 criteria.
Time frame: Up to 6 months
Cohort 1: Progression-Free Survival (PFS) of 4 months
Cohort 1: Survival curve was plotted using Kaplan-Meier method. In the curve, the corresponding cumulative survival rate and 95% confidence interval for progression-free survival of 4 months were obtained.
Time frame: Up to 4 months
Cohort 1: Overall response rate (ORR)
Cohort 1: The percentage of subjects with complete (CR) or partial response (PR) as determined by the investigator according to the RECIST 1.1 criteria.
Time frame: Baseline up to 96 weeks
Cohort 2: Progression-Free Survival (PFS) of 6 months
Cohort 2: Kaplan-Meier method was used to plot the survival curve with the corresponding cumulative survival rate and 95% confidence interval (95% CI) when the progression-free survival time was 6 months. The overall population and 2 dose groups were counted separately (including participants in the safe introduction period and the extended period).
Time frame: Up to 6 months
Progression-Free Survival (PFS) of Cohort 1 and Cohort 2
The time between medication or random initiation and objective progression of disease or death from any cause, whichever comes first.
Time frame: Up to 96 weeks
Disease control rate (DCR) of Cohort 1 and Cohort 2
The percentage of subjects with complete response (CR), partial response (PR), or stable disease (SD) for 6 weeks or more as determined by the investigator based on RECIST 1.1.
Time frame: Up to 6 weeks
Duration of response(DOR) of Cohort 1 and Cohort 2
For subjects whose optimal response was complete response (CR) or partial response (PR), defined as from the date when tumor response was first documented to the date when disease progression was first documented or the date of death from any cause, whichever came first.
Time frame: Baseline up to 96 weeks
Overall survival (OS) of Cohort 1 and Cohort 2
From randomization to the time of death from any cause.
Time frame: Baseline up to 96 weeks
Adverse event rate of Cohort 1 and Cohort 2
Incidence and severity of adverse events (AES) and serious adverse events (SAEs), abnormal laboratory test indicators and treatment-related adverse events (TEAEs).
Time frame: Baseline up to 96 weeks
Incidence of Anti-drug antibody (ADA )and Neutralizing Antibody( NAb )
The positive rates of immunogenicity (ADA and NAb) in subjects were summarized and descriptive statistical analysis was performed.
Time frame: 30 minutes before administration on day 1 of cycles 1, 2, 4 and 8 (each cycle is 21 days), day 90 after the last administration (±7 days)
Ran from Feb 2024 to primary completion in Jun 2025, 16 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. →